Recursion Pharmaceuticals faces slow growth and cash burn despite AI drug discovery partnerships.

Recursion Pharmaceuticals continues to hold its stock as it faces challenges from slow revenue growth and competitive pressure in AI-driven drug discovery. While partnerships with Genentech/Roche and Sanofi have brought over $500 million in milestone payments, the company’s internal drug pipeline, especially REC-4881 for FAP, needs more data and is unlikely to generate significant revenue before 2030. Ongoing cash burn, risk of dilution, and rising operating expenses overshadow the modest progress in its pipeline and partnerships, keeping the stock price rangebound for now.